Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, California.

Corresponding author: Mitchell D. Creinin, MD, University of California, Davis, Sacramento, CA; email: [email protected].

Financial Disclosure Mitchell D. Creinin has received speaking honoraria from Gedeon Richter and Mayne, serves on an Advisory Boards for Evofem, Fuji Pharma, Mayne, Merck, Searchlight, and TherapeuticsMD, and is a consultant for Estetra SRL, Libbs, Mayne, and Medicines360. The Department of Obstetrics and Gynecology, University of California, Davis, receives contraceptive research funding for Dr. Creinin from Chemo Research SL, Evofem, HRA Pharma, Medicines360, Merck, and Sebela. Courtney Baker did not report any potential conflicts of interest.

This article discusses Liletta, which is scheduled for approval for 8-year use by the U.S. Food and Drug Administration in November 2022.

Each author has confirmed compliance with the journal's requirements for authorship.

Peer reviews and author correspondence are available at https://links.lww.com/AOG/C892.